In studies on TLR-mediated enhancement of CSC stemness, in breast cancer, TLR3 activation drives the conversion of non-CSCs into CSCs by synergistically activating the β-catenin and NF-κB pathways, leading to tumor recurrence. Here, NFKB1 is linked to breast carcinoma.